Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pegaptanib Clear all

Conditions: Macular Degeneration
Interventions: Pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: PDR
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: Up to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: pegaptanib sodium injection; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 50 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 4
States / cities: Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more

Conditions: Age-Related Macular Degeneration (AMD)
Interventions: pegaptanib sodium (Macugen); Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Abilene, Texas

Conditions: Wet AMD
Interventions: Lucentis; Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Ocular Histoplasmosis, Choroidal Neovascularization
Interventions: pegaptanib sodium; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Macular Edema Associated With Diabetes Mellitus
Interventions: Standard of Care, Macugen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Iris Neovascularization, Diabetic Retinopathy
Interventions: Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP); Other · Procedure
Lead sponsor: Hermann Eye Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Age-Related Macular Degeneration
Interventions: Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium); Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetic Macular Edema
Interventions: Macugen (Pegaptanib Sodium); Drug
Lead sponsor: Retina Institute of Hawaii; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Branch Retinal Vein Occlusion
Interventions: pegaptanib sodium (Macugen); Drug
Lead sponsor: Palmetto Retina Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina

Conditions: Macular Degeneration
Interventions: pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 20
States / cities: Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: Macugen ® (pegaptanib sodium); Drug
Lead sponsor: Valley Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: McAllen, Texas

Conditions: Retinal Vein Occlusion
Interventions: pegaptanib sodium; Drug
Lead sponsor: Eyetech Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 35
States / cities: Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Cystoid Macular Edema
Interventions: Pegaptanib Sodium, Control; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Macular Edema
Interventions: Macugen® pegaptanib sodium; Drug
Lead sponsor: Valley Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: McAllen, Texas

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Macular Degeneration
Interventions: VEGF Trap; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more

Conditions: Proliferative Diabetic Retinopathy
Interventions: Macugen, Sham; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Macular Degeneration, Choroidal Neovascularization
Interventions: Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Uveitis, Cystoid Macular Edema
Interventions: Pegaptanib; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Cystoid Macular Edema
Interventions: Pegaptanib sodium, Control; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Macugen for Histoplasmosis

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

Neovascular Age-related Macular Degeneration

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics